Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
1.
Surg Pathol Clin ; 16(2): 197-211, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: covidwho-2269851

RESUMEN

Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 and is associated with pronounced hematopathologic findings. Peripheral blood features are heterogeneous and very often include neutrophilia, lymphopenia, myeloid left shift, abnormally segmented neutrophils, atypical lymphocytes/plasmacytoid lymphocytes, and atypical monocytes. Bone marrow biopsies and aspirates are often notable for histiocytosis and hemophagocytosis, whereas secondary lymphoid organs may exhibit lymphocyte depletion, pronounced plasmacytoid infiltrates, and hemophagocytosis. These changes are reflective of profound innate and adaptive immune dysregulation, and ongoing research efforts continue to identify clinically applicable biomarkers of disease severity and outcome.


Asunto(s)
COVID-19 , Linfopenia , Humanos , SARS-CoV-2 , Linfopenia/diagnóstico
2.
BMC Infect Dis ; 22(1): 295, 2022 Mar 26.
Artículo en Inglés | MEDLINE | ID: covidwho-1765437

RESUMEN

BACKGROUND: In the Emergency Department (ED), early and accurate recognition of infection is crucial to prompt antibiotic therapy but the initial presentation of patients is variable and poorly characterized. Lymphopenia is commonly associated with bacteraemia and poor outcome in intensive care unit patients. The objective of this retrospective study was to assess the prevalence of community-acquired infection in a cohort of unselected patients admitted to the ED with undifferentiated symptoms and severe lymphopenia. METHODS: This is a retrospective single-center study conducted over a 1 year-period before the COVID-19 pandemic. Consecutive adult patients admitted to the ED with severe lymphopenia (lymphocyte count < 0.5 G/L) were studied. Patients with hematological or oncological diseases, HIV infection, hepato-cellular deficiency, immunosuppression, or patients over 85 years old were excluded. Diagnoses of infection were validated by an independent adjudication committee. The association between various parameters and infection was assessed using a multivariate logistic regression analysis. RESULTS: Of 953 patients admitted to the ED with severe lymphopenia, 245 were studied (148 men; mean age: 63 ± 19 years). Infection was confirmed in 159 patients (65%) (bacterial: 60%, viral: 30%, other: 10%). Only 61 patients (25%) were referred to the ED for a suspected infection. In the univariate analysis, SIRS criteria (OR: 5.39; 95%CI: 3.04-9.70; p < 0.001) and temperature ≥ 38.3 °C (OR: 10.95; 95%CI: 5.39-22.26; p < 0.001) were strongly associate with infection. In the multivariate analysis, only SIRS criteria (OR: 2.4; 95%CI: 1.48-3.9; p < 0.01) and fever (OR: 3.35; 95%CI: 1.26-8.93; p = 0.016) were independently associated with infection. CONCLUSIONS: The prevalence of underlying infection is high in patients admitted to the ED with lymphopenia, irrespective of the reason for admission. Whether lymphopenia could constitute a valuable marker of underlying infection in this clinical setting remains to be confirmed prospectively in larger cohorts. TRIAL REGISTRATION: No registration required as this is a retrospective study.


Asunto(s)
COVID-19 , Infecciones por VIH , Linfopenia , Adulto , Anciano , Anciano de 80 o más Años , COVID-19/epidemiología , Servicio de Urgencia en Hospital , Infecciones por VIH/complicaciones , Infecciones por VIH/epidemiología , Humanos , Linfopenia/diagnóstico , Masculino , Persona de Mediana Edad , Pandemias , Prevalencia , Estudios Retrospectivos
3.
Signal Transduct Target Ther ; 6(1): 418, 2021 12 10.
Artículo en Inglés | MEDLINE | ID: covidwho-1565706

RESUMEN

The systemic processes involved in the manifestation of life-threatening COVID-19 and in disease recovery are still incompletely understood, despite investigations focusing on the dysregulation of immune responses after SARS-CoV-2 infection. To define hallmarks of severe COVID-19 in acute disease (n = 58) and in disease recovery in convalescent patients (n = 28) from Hannover Medical School, we used flow cytometry and proteomics data with unsupervised clustering analyses. In our observational study, we combined analyses of immune cells and cytokine/chemokine networks with endothelial activation and injury. ICU patients displayed an altered immune signature with prolonged lymphopenia but the expansion of granulocytes and plasmablasts along with activated and terminally differentiated T and NK cells and high levels of SARS-CoV-2-specific antibodies. The core signature of seven plasma proteins revealed a highly inflammatory microenvironment in addition to endothelial injury in severe COVID-19. Changes within this signature were associated with either disease progression or recovery. In summary, our data suggest that besides a strong inflammatory response, severe COVID-19 is driven by endothelial activation and barrier disruption, whereby recovery depends on the regeneration of the endothelial integrity.


Asunto(s)
Anticuerpos Antivirales/sangre , Proteínas Sanguíneas/metabolismo , COVID-19/diagnóstico , Síndrome de Liberación de Citoquinas/diagnóstico , Endotelio Vascular/virología , Linfopenia/diagnóstico , SARS-CoV-2/patogenicidad , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , COVID-19/inmunología , COVID-19/mortalidad , COVID-19/virología , Quimiocina CXCL10/sangre , Quimiocina CXCL9/sangre , Análisis por Conglomerados , Convalecencia , Síndrome de Liberación de Citoquinas/inmunología , Síndrome de Liberación de Citoquinas/mortalidad , Síndrome de Liberación de Citoquinas/virología , Progresión de la Enfermedad , Endotelio Vascular/inmunología , Granulocitos/inmunología , Granulocitos/virología , Factores de Crecimiento de Célula Hematopoyética/sangre , Factor de Crecimiento de Hepatocito/sangre , Humanos , Unidades de Cuidados Intensivos , Subunidad p40 de la Interleucina-12/sangre , Interleucina-6/sangre , Interleucina-8/sangre , Células Asesinas Naturales/inmunología , Células Asesinas Naturales/virología , Lectinas Tipo C/sangre , Linfopenia/inmunología , Linfopenia/mortalidad , Linfopenia/virología , Células Plasmáticas/inmunología , Células Plasmáticas/virología , Análisis de Supervivencia , Linfocitos T/inmunología , Linfocitos T/virología
4.
Trials ; 22(1): 674, 2021 Oct 02.
Artículo en Inglés | MEDLINE | ID: covidwho-1448257

RESUMEN

BACKGROUND: Moderate/severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state. This is a study protocol of an open-label, multi-center, double-arm, randomized, dose-finding phase I/II clinical trial to evaluate the safety, tolerability, alloreactivity, and efficacy of the administration of allogeneic memory T cells and natural killer (NK) cells in COVID-19 patients with lymphopenia and/or pneumonia. The aim of the study is to determine the safety and the efficacy of the recommended phase 2 dose (RP2D) of this treatment for patients with moderate/severe COVID-19. METHODS: In the phase I trial, 18 patients with COVID-19-related pneumonia and/or lymphopenia with no oxygen requirement or with an oxygen need of ≤ 2.5 liters per minute (lpm) in nasal cannula will be assigned to two arms, based on the biology of the donor and the patient. Treatment of arm A consists of the administration of escalating doses of memory T cells, plus standard of care (SoC). Treatment of arm B consists of the administration of escalating doses of NK cells, plus SoC. In the phase II trial, a total of 182 patients with COVID-19-related pneumonia and/or lymphopenia requiring or not oxygen supplementation but without mechanical ventilation will be allocated to arm A or B, considering HLA typing. Within each arm, they will be randomized in a 1:1 ratio. In arm A, patients will receive SoC or RP2D for memory T cells plus the SoC. In arm B, patients will receive SoC or RP2D for NK cells plus the SoC. DISCUSSION: We hypothesized that SARS-CoV-2-specific memory T-lymphocytes obtained from convalescent donors recovered from COVID-19 can be used as a passive cell immunotherapy to treat pneumonia and lymphopenia in moderate/severe patients. The lymphopenia induced by COVID-19 constitutes a therapeutic window that may facilitate donor engraftment and viral protection until recovery. TRIAL REGISTRATION: ClinicalTrials.gov NCT04578210 . First Posted : October 8, 2020.


Asunto(s)
COVID-19 , Linfopenia , Ensayos Clínicos Fase I como Asunto , Ensayos Clínicos Fase II como Asunto , Humanos , Memoria Inmunológica , Células Asesinas Naturales , Linfopenia/diagnóstico , Linfopenia/terapia , Estudios Multicéntricos como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , SARS-CoV-2 , Linfocitos T , Resultado del Tratamiento
6.
Sci Rep ; 11(1): 13840, 2021 07 05.
Artículo en Inglés | MEDLINE | ID: covidwho-1383121

RESUMEN

To characterize the new SARS-Co-V-2 related multisystem inflammatory syndrome in children (MIS-C) among Israeli children and to compare it with Kawasaki disease (KD). We compared, in two medical centers, the clinical and laboratory characteristics of MIS-C, KD and an intermediate group, which met the case definitions of both conditions. MIS-C patients were older, were more likely to be hypotensive, to have significant gastrointestinal symptoms, lymphopenia and thrombocytopenia and to have non-coronary abnormal findings in their echocardiogram. Lymphopenia was an independent predictor of MIS-C. Most of our MIS-C patients responded promptly to corticosteroid therapy. KD incidence in both centers was similar in 2019 and 2020. Although there is clinical overlap between KD and MIS-C, these are separate entities. Lymphopenia clearly differentiates between these entities. MIS-C patients may benefit from corticosteroids as first-line therapy.


Asunto(s)
COVID-19/complicaciones , COVID-19/patología , Linfopenia/patología , Síndrome Mucocutáneo Linfonodular/diagnóstico , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico , Adolescente , Corticoesteroides/uso terapéutico , Adulto , COVID-19/diagnóstico , COVID-19/virología , Niño , Preescolar , Diagnóstico Diferencial , Femenino , Humanos , Linfopenia/diagnóstico , Masculino , Síndrome Mucocutáneo Linfonodular/tratamiento farmacológico , Síndrome Mucocutáneo Linfonodular/patología , Síndrome Mucocutáneo Linfonodular/virología , Factores de Riesgo , SARS-CoV-2/patogenicidad , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , Síndrome de Respuesta Inflamatoria Sistémica/patología , Síndrome de Respuesta Inflamatoria Sistémica/virología , Adulto Joven , Tratamiento Farmacológico de COVID-19
7.
J Am Coll Surg ; 233(3): 435-444.e1, 2021 09.
Artículo en Inglés | MEDLINE | ID: covidwho-1260777

RESUMEN

BACKGROUND: High scores in the Medically Necessary, Time-Sensitive (MeNTS) scoring system, used for elective surgical prioritization during the coronavirus disease 2019 pandemic, are assumed to be associated with worse outcomes. We aimed to evaluate the MeNTS scoring system in patients undergoing elective surgery during restricted capacity of our institution, with or without moderate or severe postoperative complications. STUDY DESIGN: In this prospective observational study, MeNTS scores of patients undergoing elective operations during May and June 2020 were calculated. Postoperative complication severity (classified as Group Clavien-Dindo < II or Group Clavien-Dindo ≥ II), as well as Duke Activity Index, American Society of Anesthesiologists (ASA) physical status, presence of smoking, leukocytosis, lymphopenia, elevated C-reactive protein (CRP), operation and anesthesia characteristics, intensive care requirement and duration, length of hospital stay, rehospitalization, and mortality were noted. RESULTS: There were 223 patients analyzed. MeNTS score was higher in the Clavien-Dindo ≥ II Group compared with the Clavien-Dindo < II Group (50.98 ± 8.98 vs 44.27 ± 8.90 respectively, p < 0.001). Duke activity status index (DASI) scores were lower, and American Society of Anesthesiologists physical status class, presence of smoking, leukocytosis, lymphopenia, elevated CRP, and intensive care requirement were higher in the Clavien-Dindo ≥ II Group (p < 0.01). Length of hospital stay was longer in the Clavien-Dindo ≥ II Group (15 [range 2-90] vs 4 [1-30] days; p < 0.001). Mortality was observed in 8 patients. Area under the receiver operating characteristic curve of MeNTS and DASI were 0.69 and 0.71, respectively, for predicting moderate/severe complications. CONCLUSIONS: Although significant, MeNTS score had low discriminating power in distinguishing patients with moderate/severe complications. Incorporation of a cardiovascular functional capacity measure could improve the scoring system.


Asunto(s)
COVID-19/epidemiología , Procedimientos Quirúrgicos Electivos/efectos adversos , Pandemias , Complicaciones Posoperatorias/clasificación , Triaje/métodos , Anestesia , Proteína C-Reactiva/análisis , COVID-19/diagnóstico , Cuidados Críticos , Procedimientos Quirúrgicos Electivos/clasificación , Procedimientos Quirúrgicos Electivos/mortalidad , Femenino , Prioridades en Salud , Humanos , Tiempo de Internación , Leucocitosis/diagnóstico , Linfopenia/diagnóstico , Masculino , Persona de Mediana Edad , Readmisión del Paciente , Rendimiento Físico Funcional , Complicaciones Posoperatorias/mortalidad , Estudios Prospectivos , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad , Fumar , Resultado del Tratamiento , Turquia
8.
J Med Virol ; 93(9): 5474-5480, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-1219314

RESUMEN

In this study, laboratorial parameters of hospitalized novel coronavirus (COVID-19) patients, who were complicated with severe pneumonia, were compared with the findings of cytokine storm developing in macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (sHLH). Severe pneumonia occurred as a result of cytokine storm in some patients who needed intensive care unit (ICU), and it is aimed to determine the precursive parameters in this situation. Also in this study, the aim is to identify laboratory criteria that predict worsening disease and ICU intensification, as well as the development of cytokine storm. This article comprises a retrospective cohort study of patients admitted to a single institution with COVID-19 pneumonia. This study includes 150 confirmed COVID-19 patients with severe pneumonia. When they were considered as severe pneumonia patients, the clinic and laboratory parameters of this group are compared with H-score criteria. Patients are divided into two subgroups; patients with worsened symptoms who were transferred into tertiary ICU, and patients with stable symptoms followed in the clinic. For the patients with confirmed COVID-19 infection, after they become complicated with severe pneumonia, lymphocytopenia (55.3%), anemia (12.0%), thrombocytopenia (19.3%), hyperferritinemia (72.5%), hyperfibrinogenemia (63.7%) and elevated lactate dehydrogenase (LDH) (90.8%), aspartate aminotransaminase (AST) (31.3%), alanine aminotransaminase (ALT) (20.7%) are detected. There were no significant changes in other parameters. Blood parameters between the pre-ICU period and the ICU period (in which their situation had been worsened and acute respiratory distress syndrome [ARDS] was developed) were also compared. In the latter group lymphocyte levels were found significantly reduced (p = 0.01), and LDH, highly sensitive troponin (hs-troponin), procalcitonin, and triglyceride levels were significantly increased (p < 0.05). In addition, there was no change in hemoglobin, leukocyte, platelet, ferritin, and liver function test levels, including patients who developed ARDS, similar to the cytokine storm developed in MAS/sHLH. COVID-19 pneumonia has similar findings as hyperinflammatory syndromes but does not seem to have typical features as in cytokine storm developed in MAS/sHLH. In the severe patient group who has started to develop ARDS signs, a decrease in lymphocyte level in addition to the elevated LDH, hs-troponin, procalcitonin, and triglyceride levels can be a predictor in progression to ICU admission and could help in the planning of anti-cytokine therapy.


Asunto(s)
COVID-19/patología , Síndrome de Liberación de Citoquinas/patología , Linfohistiocitosis Hemofagocítica/patología , Síndrome de Activación Macrofágica/patología , SARS-CoV-2/patogenicidad , Anciano , Alanina Transaminasa/sangre , Anemia/sangre , Anemia/diagnóstico , Anemia/inmunología , Anemia/patología , Aspartato Aminotransferasas/sangre , Biomarcadores/sangre , COVID-19/sangre , COVID-19/diagnóstico , COVID-19/inmunología , Síndrome de Liberación de Citoquinas/sangre , Síndrome de Liberación de Citoquinas/diagnóstico , Síndrome de Liberación de Citoquinas/inmunología , Diagnóstico Diferencial , Progresión de la Enfermedad , Femenino , Fibrinógeno/metabolismo , Humanos , Hiperferritinemia/sangre , Hiperferritinemia/diagnóstico , Hiperferritinemia/inmunología , Hiperferritinemia/patología , Unidades de Cuidados Intensivos , L-Lactato Deshidrogenasa/sangre , Linfohistiocitosis Hemofagocítica/sangre , Linfohistiocitosis Hemofagocítica/diagnóstico , Linfohistiocitosis Hemofagocítica/inmunología , Linfopenia/sangre , Linfopenia/diagnóstico , Linfopenia/inmunología , Linfopenia/patología , Síndrome de Activación Macrofágica/sangre , Síndrome de Activación Macrofágica/diagnóstico , Síndrome de Activación Macrofágica/inmunología , Masculino , Persona de Mediana Edad , Polipéptido alfa Relacionado con Calcitonina/sangre , Estudios Retrospectivos , Trombocitopenia/sangre , Trombocitopenia/diagnóstico , Trombocitopenia/inmunología , Trombocitopenia/patología , Triglicéridos/sangre , Troponina/sangre
9.
J Med Virol ; 93(2): 794-802, 2021 02.
Artículo en Inglés | MEDLINE | ID: covidwho-1196404

RESUMEN

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was found in the intestines and feces, but its clinical significance is not completely clear. We aim to characterize the longitudinal test results of SARS-CoV-2 RNA in anal swabs and to explore the association with disease severity. METHODS: We included laboratory-confirmed coronavirus disease 2019 (COVID-19) patients, who were hospitalized in Guangzhou Eighth People's Hospital and excluded those who had not received anal swabs for SARS-COV-2 RNA testing. Epidemiological, clinical, and laboratory data were obtained. Throat swabs and anal swabs were collected periodically for SARS-COV-2 RNA detection. RESULTS: Two hundred and seventeen eligible patients (median aged 50 years, 50.2% were females) were analyzed. 21.2% (46/217) of the patients were detected with SARS-CoV-2 RNA in anal swabs. The duration of viral RNA was longer, but the viral load was lower in anal swabs than throat swabs in the early stage of the disease. During a median follow-up of 20 days, 30 (13.8%) patients were admitted to the intensive care unit (ICU) for high-flow nasal cannula or higher-level oxygen support measures to correct hypoxemia. Detectable viral RNA in anal swabs (adjusted hazard ratio [aHR], 2.50; 95% confidence interval [CI], 1.20-5.24), increased C-reactive protein (aHR, 3.14; 95% CI, 1.35-7.32) and lymphocytopenia (aHR, 3.12; 95% CI, 1.46-6.67) were independently associated with ICU admission. The cumulative incidence of ICU admission was higher among patients with detectable viral RNA in anal swabs (26.3% vs 10.7%, P = .006). CONCLUSION: Detectable SARS-CoV-2 RNA in the digestive tract was a potential warning indicator of severe disease.


Asunto(s)
Canal Anal/virología , COVID-19/diagnóstico , Linfopenia/diagnóstico , ARN Viral/genética , SARS-CoV-2/genética , Adulto , Antivirales/uso terapéutico , Proteína C-Reactiva/metabolismo , COVID-19/patología , COVID-19/terapia , COVID-19/virología , Prueba de COVID-19 , Cloroquina/uso terapéutico , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Indoles/uso terapéutico , Unidades de Cuidados Intensivos/estadística & datos numéricos , Linfopenia/patología , Linfopenia/terapia , Linfopenia/virología , Masculino , Persona de Mediana Edad , Oseltamivir/uso terapéutico , Faringe/virología , Estudios Retrospectivos , SARS-CoV-2/patogenicidad , Índice de Severidad de la Enfermedad , Carga Viral/efectos de los fármacos
10.
Int J Lab Hematol ; 43(5): 1237-1242, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: covidwho-1175057

RESUMEN

INTRODUCTION: Outbreak of corona virus disease in 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Our aim is to document hematological parameters of patients with COVID-19 during initial stage of diagnosis and to identify early hematological indicators of severe infection. MATERIALS AND METHODS: This retrospective study was conducted at Shifa International Hospital, Pakistan from April to November 2020. Patients hospitalized with COVID-19, diagnosed on RT-PCR and had a complete blood count (CBC) done within 48 hours of diagnosis were included. Data was analyzed using IBM® SPSS Statistics. RESULTS: A total of 425 patients were included in this study out of whom 272(64%) were males. The mean age was 55.61 ± 17.84 years. 95 patients (22.4%) had normal blood counts within 48 hours of COVID-19 diagnosis. Cytopenias were seen in 193(45.4%) patients. There were 75(17.6%) mortalities during the study period. Chi-square test showed that thrombocytopenia, lymphopenia and neutrophilic leucocytosis were significantly associated with mortality (P = .037, P < .001, P < .001 respectively) and need for ventilator (P = .009, P < .001, P < .001, respectively). Neutrophilia was also associated with development of Acute Respiratory Distress Syndrome (P < .001). On ROC analysis, Neutrophil-to-Lymphocyte Ratio yielded an area under the curve (AUC) of 0.693 and 0.660 for the outcomes mortality and need for ventilator, respectively. For a subset of 288 patients who had D-dimer levels checked within 48 hours of COVID-19 diagnosis, the AUC for mortality and ventilator need was 0.708 and 0.671, respectively. CONCLUSION: Hematological indices are vital indicators in the prognosis and risk stratification of COVID-19 during initial stages of disease.


Asunto(s)
COVID-19/sangre , Adulto , Anciano , Recuento de Células Sanguíneas , COVID-19/complicaciones , COVID-19/diagnóstico , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Hospitalización , Humanos , Recuento de Leucocitos , Linfopenia/sangre , Linfopenia/diagnóstico , Linfopenia/etiología , Masculino , Persona de Mediana Edad , Pakistán/epidemiología , Pronóstico , Estudios Retrospectivos , SARS-CoV-2/aislamiento & purificación , Índice de Severidad de la Enfermedad , Trombocitopenia/sangre , Trombocitopenia/diagnóstico , Trombocitopenia/etiología
11.
J Clin Endocrinol Metab ; 106(7): 1994-2009, 2021 06 16.
Artículo en Inglés | MEDLINE | ID: covidwho-1133638

RESUMEN

CONTEXT: Lymphopenia is a key feature of immune dysfunction in patients with bacterial sepsis and coronavirus disease 2019 (COVID-19) and is associated with poor clinical outcomes, but the cause is largely unknown. Severely ill patients may present with thyroid function abnormalities, so-called nonthyroidal illness syndrome, and several studies have linked thyrotropin (thyroid stimulating hormone, TSH) and the thyroid hormones thyroxine (T4) and 3,5,3'-triiodothyronine (T3) to homeostatic regulation and function of lymphocyte populations. OBJECTIVE: This work aimed to test the hypothesis that abnormal thyroid function correlates with lymphopenia in patients with severe infections. METHODS: A retrospective analysis of absolute lymphocyte counts, circulating TSH, T4, free T4 (FT4), T3, albumin, and inflammatory biomarkers was performed in 2 independent hospitalized study populations: bacterial sepsis (n = 224) and COVID-19 patients (n = 161). A subgroup analysis was performed in patients with severe lymphopenia and normal lymphocyte counts. RESULTS: Only T3 significantly correlated (ρ = 0.252) with lymphocyte counts in patients with bacterial sepsis, and lower concentrations were found in severe lymphopenic compared to nonlymphopenic patients (n = 56 per group). Severe lymphopenic COVID-19 patients (n = 17) showed significantly lower plasma concentrations of TSH, T4, FT4, and T3 compared to patients without lymphopenia (n = 18), and demonstrated significantly increased values of the inflammatory markers interleukin-6, C-reactive protein, and ferritin. Remarkably, after 1 week of follow-up, the majority (12 of 15) of COVID-19 patients showed quantitative recovery of their lymphocyte numbers, whereas TSH and thyroid hormones remained mainly disturbed. CONCLUSION: Abnormal thyroid function correlates with lymphopenia in patients with severe infections, like bacterial sepsis and COVID-19, but future studies need to establish whether a causal relationship is involved.


Asunto(s)
COVID-19/complicaciones , Síndromes del Eutiroideo Enfermo/diagnóstico , Linfopenia/inmunología , Sepsis/complicaciones , Anciano , Anciano de 80 o más Años , COVID-19/sangre , COVID-19/inmunología , Síndromes del Eutiroideo Enfermo/sangre , Síndromes del Eutiroideo Enfermo/inmunología , Femenino , Grecia , Humanos , Recuento de Linfocitos , Linfopenia/sangre , Linfopenia/diagnóstico , Masculino , Países Bajos , Estudios Retrospectivos , SARS-CoV-2/inmunología , Sepsis/sangre , Sepsis/inmunología , Hormonas Tiroideas/sangre , Hormonas Tiroideas/inmunología , Tirotropina/sangre , Tirotropina/inmunología
12.
Medicine (Baltimore) ; 100(5): e23991, 2021 Feb 05.
Artículo en Inglés | MEDLINE | ID: covidwho-1087853

RESUMEN

ABSTRACT: Since the first infected case of Coronavirus Disease 2019 (COVID-19) was reported in Wuhan, China in December 2019, the virus has spread swiftly, inflicting upon millions of people around the globe. The objective of the study is to investigate and analyze the clinical characteristics and outcomes of patients infected with COVID-19 in Wuxi, China.Cross-sectional study.The Fifth People's Hospital of Wuxi, China.A total of 48 COVID-19 patients were enrolled in the study from 23 January 2020 to 8 March 2020, and the clinical data of these subjects were collected.Epidemiological, clinical, laboratory, and radiologic characteristics, as well as treatment and outcome data, were collected and analyzed.Of these 48 patients with confirmed COVID-19, 3 were mild cases (6.3%), 44 were moderate cases (91.7%), 1 was severe case (2.1%). The median age of the subjects was 45 years (interquartile range [IQR], 24-59; range, 5-75 years). Twenty-five of the patients (52.1%) were male and 23 (47.9%) were female. Twenty-eight cases (58.3%) returned to Wuxi, Jiangsu Province. Thirty-four (70.8%) cases were infected due to clustering epidemic and 29 cases (85.3%) were attributable to family-clustering epidemic. No obvious clinical symptoms were observed in the cohort of patients, except for 3 mild cases. The most common symptoms include fever (41 [85.4%]), cough (28 [58.3%]), asthenia (13 [27.1%]), expectoration (11 [22.9%]), diarrhea (10 [20.8%]), and dyspnea (5 [10.4%]). Seventeen (35.4%) patients had lower lymphocyte values than baseline, 31 patients (64.6%) had higher d-dimers to exceed the normal range. The distribution of high-resolution computed tomography (HRCT)-positive lesions were as follows: left lung in 5 cases (10.4%), right lung in 9 cases (18.8%), and bilateral lungs in 31 cases (64.6%). In terms of density of lesions: 28 cases (58.3%) showed ground glass shadows in the lung, 7 cases (14.6%) showed solid density shadows, and 10 cases (20.8%) showed mixed density shadows. Extrapulmonary manifestations found that mediastinal lymph nodes were enlarged in 2 cases (4.2%) and that pleural effusion was present in 1 case (2.1%). All patients underwent treatment in quarantine. Forty-five (93.8%) patients received antiviral treatments, 22 (45.8%) patients received antibacterial treatments, 6 (12.5%) patients received glucocorticoid treatments, 2 (4.2%) patients received high flow oxygen inhalation treatments, and 6 (12.5%) patients received noninvasive ventilation treatments. As of 8 March 2020, all 48 patients included in this study were cured. The average time of hospitalization of the 48 patients was 18 ±â€Š6 (mean ±â€ŠSD) days, the average time of the lesion resorption was 11 ±â€Š4 days, and the average time taken to achieve negativity in the result of nucleic acid examination was (10 ±â€Š4) days.The epidemiological characteristics of 48 COVID-19 patients in Wuxi were mainly imported cases and clustered cases. The clinical manifestations of these patients were mainly fever and cough. Laboratory results showed that the lymphocytopenia and increased d-dimer are positively correlated with disease severity. Pulmonary imaging showed unilateral or bilateral ground glass infiltration. Most of the patients entered clinical recovery stage within 15 days after hospitalization.


Asunto(s)
COVID-19 , Tos , Fiebre , Hospitalización/estadística & datos numéricos , Atención al Paciente , SARS-CoV-2/aislamiento & purificación , Evaluación de Síntomas/estadística & datos numéricos , COVID-19/sangre , COVID-19/epidemiología , COVID-19/fisiopatología , COVID-19/terapia , China/epidemiología , Análisis por Conglomerados , Tos/diagnóstico , Tos/etiología , Salud de la Familia/estadística & datos numéricos , Femenino , Fiebre/diagnóstico , Fiebre/etiología , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Humanos , Linfopenia/diagnóstico , Linfopenia/etiología , Masculino , Persona de Mediana Edad , Atención al Paciente/métodos , Atención al Paciente/estadística & datos numéricos , Radiografía Torácica/estadística & datos numéricos , Tomografía Computarizada por Rayos X/métodos
15.
J Korean Med Sci ; 35(47): e418, 2020 Dec 07.
Artículo en Inglés | MEDLINE | ID: covidwho-963328

RESUMEN

BACKGROUND: Most patients including health care workers (HCWs) survived the coronavirus disease 2019 (COVID-19), however, knowledge about the sequelae of COVID-19 after discharge remains limited. METHODS: A prospectively observational 3-month follow-up study evaluated symptoms, dynamic changes of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) IgG and IgM, lung function, and high resolution computed tomography (HRCT) of survivors of COVID-19 after discharge at Wuhan Union Hospital, China. RESULTS: Seventy-six survivors (55 females) with a mean age of 41.3 ± 13.8 years were enrolled, and 65 (86%) were HCWs. A total of 69 (91%) patients had returned to their original work at 3-months after discharge. Most of the survivors had symptoms including fever, sputum production, fatigue, diarrhea, dyspnea, cough, chest tightness on exertion and palpitations in the three months after discharge. The serum troponin-I levels during the acute illness showed high correlation with the symptom of fatigue after hospital discharge (r = 0.782; P = 0.008) and lymphopenia was correlated with the symptoms of chest tightness and palpitations on exertion of patients after hospital discharge (r = -.285, P = 0.027; r = -.363, P = 0.004, respectively). The mean values of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity and diffusion capacity were all normal (> 80% predicted) and lung HRCTs returned to normal in most of the patients (82%), however, 42% of survivors had mild pulmonary function abnormalities at 3-months after discharge. SARS-CoV-2 IgG turned negative in 11% (6 of 57 patients), 8% (4 of 52 patients) and 13% (7 of 55 patients), and SARS-CoV-2 IgM turned negative in 72% (41 of 57 patients), 85% (44 of 52 patients) and 87% (48 of 55 patients) at 1-month, 2-months and 3-months after discharge, respectively. CONCLUSION: Infection by SARS-CoV-2 caused some mild impairments of survivors within the first three months of their discharge and the duration of SARS-CoV-2 antibody was limited, which indicates the necessity of long-term follow-up of survivors of COVID-19.


Asunto(s)
COVID-19/patología , Pulmón/fisiología , Adulto , Anciano , Anticuerpos Antivirales/sangre , COVID-19/virología , Femenino , Estudios de Seguimiento , Volumen Espiratorio Forzado , Humanos , Pulmón/diagnóstico por imagen , Linfopenia/diagnóstico , Masculino , Persona de Mediana Edad , Alta del Paciente , SARS-CoV-2/inmunología , SARS-CoV-2/aislamiento & purificación , Sobrevivientes , Factores de Tiempo , Tomografía Computarizada por Rayos X , Troponina I/sangre , Capacidad Vital , Adulto Joven
17.
Clin Immunol ; 221: 108611, 2020 12.
Artículo en Inglés | MEDLINE | ID: covidwho-856558

RESUMEN

Since December 2019, Coronavirus Disease 2019 (COVID-19) has emerged as a global pandemic. We aimed to investigate the clinical characteristics and analyzed the risk factors for prolonged viral RNA shedding. We retrospectively collected data from 112 hospitalized COVID-19 patients in a single center in Wuhan, China. Factors associated with prolonged viral RNA shedding (≥28 days) were investigated. Forty-nine (43.8%) patients had prolonged viral RNA shedding. Patients with prolonged viral shedding were older and had a higher rate of hypertension. Proinflammatory cytokines, including interleukin-2R (IL-2R) and tumor necrosis factor-α (TNF-α), were significantly elevated in patients with prolonged viral shedding. Multivariate analysis revealed that hypertension, older age, lymphopenia and elevated serum IL-2R were independent risk factors for prolonged viral shedding. This comprehensive investigation revealed the distinct characteristics between patients with or without prolonged viral RNA shedding. Hypertension, older age, lymphopenia and high levels of proinflammatory cytokines may be correlated with prolonged viral shedding.


Asunto(s)
COVID-19/virología , Síndrome de Liberación de Citoquinas/virología , Diabetes Mellitus/virología , Hipertensión/virología , Linfopenia/virología , ARN Viral/sangre , SARS-CoV-2/patogenicidad , Corticoesteroides/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , COVID-19/diagnóstico , COVID-19/inmunología , China , Comorbilidad , Síndrome de Liberación de Citoquinas/diagnóstico , Síndrome de Liberación de Citoquinas/tratamiento farmacológico , Síndrome de Liberación de Citoquinas/inmunología , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/inmunología , Combinación de Medicamentos , Femenino , Hospitalización , Humanos , Hidroxicloroquina/uso terapéutico , Hipertensión/diagnóstico , Hipertensión/tratamiento farmacológico , Hipertensión/inmunología , Interferones/uso terapéutico , Lopinavir/uso terapéutico , Linfopenia/diagnóstico , Linfopenia/tratamiento farmacológico , Linfopenia/inmunología , Masculino , Persona de Mediana Edad , Receptores de Interleucina-2/biosíntesis , Estudios Retrospectivos , Factores de Riesgo , Ritonavir/uso terapéutico , Índice de Severidad de la Enfermedad , Factor de Necrosis Tumoral alfa/biosíntesis , Esparcimiento de Virus , Tratamiento Farmacológico de COVID-19
19.
Signal Transduct Target Ther ; 5(1): 192, 2020 09 07.
Artículo en Inglés | MEDLINE | ID: covidwho-748172

Asunto(s)
Betacoronavirus/patogenicidad , Infecciones por Coronavirus/inmunología , Síndrome de Liberación de Citoquinas/inmunología , Regulación de la Expresión Génica/inmunología , Linfopenia/inmunología , Neumonía Viral/inmunología , Linfocitos T/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Betacoronavirus/inmunología , Biomarcadores/sangre , COVID-19 , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/genética , Infecciones por Coronavirus/mortalidad , Síndrome de Liberación de Citoquinas/diagnóstico , Síndrome de Liberación de Citoquinas/genética , Síndrome de Liberación de Citoquinas/mortalidad , Progresión de la Enfermedad , Femenino , Receptor 2 Celular del Virus de la Hepatitis A/sangre , Receptor 2 Celular del Virus de la Hepatitis A/genética , Receptor 2 Celular del Virus de la Hepatitis A/inmunología , Humanos , Indolamina-Pirrol 2,3,-Dioxigenasa/sangre , Indolamina-Pirrol 2,3,-Dioxigenasa/genética , Indolamina-Pirrol 2,3,-Dioxigenasa/inmunología , Recuento de Linfocitos , Linfopenia/diagnóstico , Linfopenia/genética , Linfopenia/mortalidad , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/diagnóstico , Neumonía Viral/genética , Neumonía Viral/mortalidad , Estudios Retrospectivos , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Análisis de Supervivencia , Linfocitos T/virología , Miembro 7 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/sangre , Miembro 7 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/genética , Miembro 7 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/inmunología , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/sangre , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/genética , Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/inmunología
20.
EMBO Mol Med ; 12(10): e13038, 2020 10 07.
Artículo en Inglés | MEDLINE | ID: covidwho-722035

RESUMEN

Early in the COVID-19 pandemic, type 2 diabetes (T2D) was marked as a risk factor for severe disease and mortality. Inflammation is central to the aetiology of both conditions where variations in immune responses can mitigate or aggravate disease course. Identifying at-risk groups based on immunoinflammatory signatures is valuable in directing personalised care and developing potential targets for precision therapy. This observational study characterised immunophenotypic variation associated with COVID-19 severity in T2D. Broad-spectrum immunophenotyping quantified 15 leucocyte populations in peripheral circulation from a cohort of 45 hospitalised COVID-19 patients with and without T2D. Lymphocytopenia and specific loss of cytotoxic CD8+ lymphocytes were associated with severe COVID-19 and requirement for intensive care in both non-diabetic and T2D patients. A morphological anomaly of increased monocyte size and monocytopenia restricted to classical CD14Hi CD16- monocytes was specifically associated with severe COVID-19 in patients with T2D requiring intensive care. Increased expression of inflammatory markers reminiscent of the type 1 interferon pathway (IL6, IL8, CCL2, INFB1) underlaid the immunophenotype associated with T2D. These immunophenotypic and hyperinflammatory changes may contribute to increased voracity of COVID-19 in T2D. These findings allow precise identification of T2D patients with severe COVID-19 as well as provide evidence that the type 1 interferon pathway may be an actionable therapeutic target for future studies.


Asunto(s)
COVID-19/patología , Diabetes Mellitus Tipo 2/patología , Monocitos/fisiología , Anciano , COVID-19/complicaciones , COVID-19/virología , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Humanos , Inmunofenotipificación , Inflamación/etiología , Interleucina-6/genética , Interleucina-6/metabolismo , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/metabolismo , Receptores de Lipopolisacáridos/metabolismo , Linfopenia/diagnóstico , Masculino , Persona de Mediana Edad , Monocitos/citología , Monocitos/patología , Factores de Riesgo , SARS-CoV-2/aislamiento & purificación , Índice de Severidad de la Enfermedad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA